Home > > > Report Detail

China Blood Product Industry Report, 2016-2019

Publisher Name :
Date: 03-Mar-2016
No. of pages: 150
Inquire Before Buying

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4, 700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.9% to China’s production-use plasma volume in 2015.

From the point of view of the product structure, human albumin is still the largest type of blood products in China, but its supply has slowed down with a lower contribution 58.8% to China’s total blood product lot release volume in 2015. In recent years, the rising lot release volume of Chinese human albumin is mainly attributed to ample supply of imported products. In 2011-2015, the lot release volume of human albumin imported by China grew at a CAGR of 23.7%, accounting for as much as 55.6% of the total. China's top four human albumin import enterprises --- Behring, Baxter, Grifols and Octapharma seized 50.7% of the total lot release volume in 2015.

China's second largest type of blood products -- human immunoglobulin (ph4) for intravenous injection saw its lot release volume jump by 31.5% year on year to 9.4 million bottles (2.5g / bottle) and its share increase to 16.9% in 2015. Over the same period, tetanus human immunoglobulin, hepatitis B immune globulin and other immune globulin products and coagulation factor products witnessed growth in lot release volume except human rabies immunoglobulin whose lot release volume declined slightly.

The research and development of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand has made the most remarkable progress in recent years. Concerning human blood coagulation factor VIII, Shanghai Xinxing had been approved to launched its human blood coagulation factor VIII, Shenzhen Weiguang had entered the new drug registration stage, Guangdong Shuanglin Bio-Pharmacy had embarked on trial production, Jiangxi Boya Bio-Pharmaceutical had gone into clinical phase III (the industrialization is expected in H2 2016), Wuhan Zhongyuan Ruide had obtained clinical approval and Harbin Pacific Biopharmaceutical had applied for clinical approval by the end of 2015.

In order to possess and effectively use plasma raw materials, enterprises are more willing to cooperate mutually in addition to acquisition. In August 2015, China Biologic Products and Xinjiang Deyuan signed a strategic cooperation agreement, under which the former should purchase at least 120/180/200 tons of plasma from the latter per year in the next three years. In 2015, Hebei Da’an Pharmaceutical and Guangdong Weilun actively planned to cooperate on the allocation of plasma fraction II + III, namely the former (it only produces human albumin now) should allocate partial plasma fraction II + III to Guangdong Weilun for the production of immunoglobulin products.

China Blood Product Industry Report, 2016-2019 focuses on the followings:


  • Market characteristics, operating environments, status quo, etc. of China blood product industry;

  • Supply and demand, competition pattern, import and export, development forecast, etc. of China blood product industry;

  • Supply and demand, competition pattern, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin;

  • Operation, blood product business and prospects of 13 major Chinese blood product companies.

China Blood Product Industry Report, 2016-2019

Table of Contents

1. Overview of Blood Product Industry
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Product Industry
2.1 Market Size
2.2 Status Quo
2.3 Supply and Demand
2.3.1 Supply
2.3.2 Demand
2.4 Competition
2.5 Operating Environment
2.5.1 International
2.5.2 Policy
2.5.3 Domestic Biopharmaceutical Market
2.6 Import and Export

3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply and Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Supply and Demand
3.2.2 Competition Pattern
3.3 Blood Coagulation Factor VIII
3.3.1 Supply and Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply and Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Supply and Demand
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Supply and Demand
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Supply and Demand
3.7.2 Competition Pattern
3.8 Human Rabies Immunoglobulin  
3.8.1 Supply and Demand
3.8.2 Competition Pattern

4. Major Chinese Manufacturers
4.1 China Biologic Products Inc. (NASDAQ: CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure  
4.1.4 Customers and Suppliers
4.1.5 R&D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Outlook and Prospects
4.2 Hualan Biological Engineering Inc. (002007.SZ)
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Customers and Suppliers  
4.2.6 R&D and Investment
4.2.7 Blood Products
4.2.8 Outlook and Prospects
4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Customers and Suppliers
4.3.6 R&D and Investment
4.3.7 Outlook and Prospects
4.4 Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO, 600161.SH)
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Customers and Suppliers
4.4.5 Gross Margin
4.4.6 R&D and Investment
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Outlook and Prospects
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Customers and Suppliers
4.5.6 R&D and Investment
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Outlook and Prospects
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Customers and Suppliers
4.6.6 R&D and Investment
4.6.7 Outlook and Prospects
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 Shanghai Institute of Biological Products Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile  
4.10.2 Blood Products
4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
4.11.1 Profile
4.11.2 Operation
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Products (Hebei Da’an Pharmaceutical Co., Ltd. and Guangdong Weilun Biological Pharmaceutical Co., Ltd.)
4.13 Shenzhen Weiguang Biological Products Co., Ltd.
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Customers and Suppliers
4.13.6 R&D and Investment
4.13.7 Outlook and Prospects

5. Summary and Forecast
5.1 Company Analysis
5.2 Growth Prediction

List of Charts

Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Function of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison between Domestic and Foreign Recombinant Blood Products in Types
Blood Product Industry Chain
Time Consumption of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
Prices of Some Blood Products in China, 2014
Blood Product Market Size in China, 2003-2015
Lot Release Volume of Blood Products in China (by Product), 2009-2015
Blood Product Structure in China (by Lot Release Volume), 2009-2015
Per Capita Frequency of Plasma Donation and Plasma Collection in China vs. the Occident
Plasma Collections in China vs. USA
Production-use Plasma Volume in China, 2008-2015
Number of Plasma Collection Stations in China, 2008-2015
Geographical Distribution of Plasma Station Resources in China by the End of 2015
Mainstream Blood Products with Medical Insurance Coverage in China
Per Capita Consumption of Blood Products in China vs. Developed Countries
Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2014
Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2015
Comparison of Chinese Blood Product Manufacturing Enterprises in Product Line
Competition Pattern of Global Blood Product Enterprises, 2013
Product Structure of Global Blood Products
Blood Products Available in Overseas Market
Global Blood Product Manufacturers
Main Policies on Chinese Blood Products
Policies on Maximum Retail Price of Drugs in China, 2014-2015
Lot Release Volume of Imported Human Albumin in China, 2008-2015
Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2015
Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2015
Consumption of Human Immunoglobulin (pH4) for Intravenous Injection per 1,000 Persons by Country, 2013 (g/1,000 persons)
Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2015
Price of Human Immunoglobulin (pH4) for Intravenous Injection in China vs. Other Countries
Average Purchase Price of Human Immunoglobulin (pH4) for Intravenous Injection of Sample Hospitals in China, 2005-2014
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2015
Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2015
Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2015
Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries (IU/Person)
Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2015
Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Prices of Human Immunoglobulin in China by Dosage, 2014
Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2015
Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2015
Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2015
Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2015
Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Rabies Incidents and Death Rate in China, 2008-2014
Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2015
Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Equity Structure of China Biologic Products by the End of 2014
Distribution of Blood Products Manufacturing Bases and Plasma Stations of CBPO, 2015
Revenue and Operating Income of CBPO, 2008-2015
Gross Margin of CBPO, 2011-2015
Revenue Breakdown of CBPO (by Product), 2011-2015
Revenue Structure of CBPO (by Product), 2010-2015
CBPO’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
R&D Costs and % of Total Revenue of CBPO, 2010-2015
Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2008-2015
Lot Release Volume of Blood Products of Guiyang Qianfeng Biological Products, 2008-2015
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2014
Revenue and Operating Income of CBPO, 2014-2019E
Revenue and Operating Income of Hualan Biological Engineering Inc., 2008-2015
Revenue of Hualan Biological Engineering Inc. (by Sector), 2008-2015
Gross Margin of Hualan Biological Engineering Inc. (by Product), 2008-2015
Hualan Biological Engineering Inc.’s Revenue from Top 5 Customers and % of Total Revenue, 2007-2014
Hualan Biological Engineering Inc.’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
Name List and Procurement Contribution of Hualan Biological Engineering Inc.’s Top 5 Suppliers, 2014
R&D Costs and % of Total Revenue of Hualan Biological Engineering Inc., 2008-2015
Types and Specifications of Blood Products of Hualan Biological Engineering Inc.
Distribution of Plasma Collection Stations of Hualan Biological Engineering Inc. by the End of 2015
Lot Release Volume of Blood Products of Hualan Biological Engineering Inc., 2008-2015
Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc., 2008-2015
Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc. (by Product), 2008-2015
Revenue and Operating Income of Hualan Biological Engineering Inc., 2014-2019E
Shanghai RAAS’s Subsidiaries and Their Operation, H1 2015 (RMB mln)
Distribution of Plasma Stations of Shanghai RAAS by the End of 2015
Revenue and Operating Income of Shanghai RAAS, 2008-2015
Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2015
Lot Release Volume of Blood Products of Tonrol Bio-Pharmaceutical, 2008-2015
Operating Revenue of Shanghai RAAS (by Product), 2008-2015
Revenue of Shanghai RAAS (by Region), 2008-2015
Gross Margin of Shanghai RAAS (by Product), 2008-2015
Shanghai RAAS’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
Shanghai RAAS’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
R&D Costs and % of Total Revenue of Shanghai RAAS, 2008-2015
Revenue and Operating Income of Shanghai RAAS, 2014-2019E
TIANTANBIO’s Subsidiaries and Their Revenue and Income, H1 2015 (RMB mln)
Revenue and Operating Income of TIANTANBIO, 2008-2015
Revenue of TIANTANBIO (by Sector), 2008-2015
Revenue of TIANTANBIO (by Region), 2008-2015
TIANTANBIO’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2014
TIANTANBIO’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
Gross Margin of TIANTANBIO (by Sector), 2008-2015
R&D Costs and % of Total Revenue of TIANTANBIO, 2009-2015
Distribution of Plasma Collection Stations of TIANTANBIO by the End of 2015
Revenue and Gross Margin of Blood Products of TIANTANBIO, 2008-2015
Lot Release Volume of Blood Products of RonSen and TIANTANBIO, 2008-2015
Revenue and Operating Income of TIANTANBIO, 2014-2019E
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2015
Operating Revenue of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2015
Gross Margin of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2013
Zhenxing Biopharmaceutical and Chemical’s Revenue from Top 5 Customers and % of Total Revenue, 2009-2014
Name List and Revenue Contribution of Zhenxing Biopharmaceutical and Chemical’s Top 5 Customers, 2014
Zhenxing Biopharmaceutical and Chemical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2014
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2015
Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2015
Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by the End of 2015
Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2015
Revenue and Gross Margin of Blood Products of Zhenxing Biopharmaceutical and Chemical, 2009-2015
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2019E
Distribution of Single Plasma Collection Stations of Jiangxi Boya Bio-Pharmaceutical by the End of 2015
Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
Revenue of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
Lot Release Volume of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014
Operating Revenue of Jiangxi Boya Bio-Pharmaceutical (by Region), 2009-2014
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
Jiangxi Boya Bio-Pharmaceutical’s Revenue from Top 5 Customers and % of Total Revenue, 2009-2015
Jiangxi Boya Bio-Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2015
R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2015
Products under Research and Progress of Jiangxi Boya Bio-Pharmaceutical as of Oct. 2015
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2019E
Distribution of Plasma Stations of Sichuan Yuanda Shuyang Pharmaceutical by the End of 2015
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2015
Lot Release Volume of Blood Products of Shanghai Institute of Biological Products, 2008-2015
Distribution of Plasma Stations of Shanghai Institute of Biological Products by the End of 2015
Distribution of Plasma Stations of Shanxi Kangbao Biological Product by the End of 2015
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2015
Distribution of Plasma Stations of Green Cross China by the End of 2015
Lot Release Volume of Blood Products of Green Cross China, 2008-2015
Revenue and Operating Income of Humanwell Healthcare, 2009-2015
Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2015
Production Industry Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2015
Revenue of Walvax Biotechnology (by Product), 2009-2015
Distribution of Single Plasma Collection Stations of Shenzhen Weiguang Biological Products by the End of 2015
Plasma Collection Volume and Production-use Plasma Volume of Shenzhen Weiguang Biological Products, 2012-2015
Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2012-2015
Capacity, Production and Sales Volume of Shenzhen Weiguang Biological Products (by Product), 2012-2015
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2012-2015
Name List and Revenue Contribution of Shenzhen Weiguang Biological Products’ Top 5 Customers, 2012-2015
Name List and Procurement Contribution of Shenzhen Weiguang Biological Products’ Top 5 Suppliers, 2012-2015
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2012-2015
Some Products under Research and Progress of Shenzhen Weiguang Biological Products by the End of 2015
Fundraising Projects of Shenzhen Weiguang Biological Products
Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2014-2019E
Number of Plasma Stations of Major Blood Product Enterprises in China as of Dec. 2015
Production-use Plasma Volume of Major Blood Product Enterprises in China, 2014-2015
Blood Product Revenue of Major Blood Product Enterprises in China, 2011-2015
Major M&A Events of Blood Product Industry in China, 2008-2015
Market Size of Blood Products in China, 2014-2019E
Gross Margin of Major Blood Product Enterprises in China, 2011-2015

  • Global Cytokine Inhibitor Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
  • Global Microbial Growth Media Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc. The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030. The market for microbial growth media is essential in microbiology and biotechnology rese......
  • Global Protein Biochip Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 92
    Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser. The global Protein Biochip market was valued at US$ 145 million i......
  • Global Isothermal Nucleic Acid Amplification Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 103
    Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction. T......
  • Global Microfluidics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 134
    According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 122
    According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
  • Global Cytokines Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period. The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
  • Global Western Blot Imagers Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period. The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
  • Global Procalcitonin Antibody Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 125
    According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs